Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
123(4):645-52
This is particularly relevant in the case of Trypanosoma species
and inhibits more than 50% of 23 targets
4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3
Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors
Ivacaftor hydrate 5109 HCl 123(4):645-52VX 770, is a drug used to treat cystic fibrosis in people with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, who account for 45% cases of cystic fibrosis, and is included in a combination drug, lumacaftor ivacaftor, which is used to treat people with cystic fibrosis who have the F508del mutation in CFTR. Ivacaftor is a "potentiator" of CFTR, meaning it increases the probability that the defective channel
US$ 1037.50
US$ 1329.00
US$ 117.00
US$ 449.00
US$ 614.50
US$ 137.50
US$ 156.50
US$ 2075.00